Evaluation and integration of cell-free DNA signatures for detection of lung cancer
Cancer Letters · 2024-11 · 604 · 217216
DOI: 10.1016/j.canlet.2024.217216 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2024-11. Verfasst von Ruyue Xue und 15 weiteren Autor:innen. Beteiligte Einrichtung: Internet Medical and System Applications of National Engineering Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. Hauptthemen laut MEDLINE: Lung Neoplasms, Biomarkers, Tumor, Cell-Free Nucleic Acids, Early Detection of Cancer. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Key Scientific Research Project of Colleges and Universities in Henan Province, Zhengzhou University, Wu Jieping Medical Foundation.
Abstract (Originalsprache)
Cell-free DNA (cfDNA) analysis has shown potential in detecting early-stage lung cancer based on non-genetic features. To distinguish patients with lung cancer from healthy individuals, peripheral blood were collected from 926 lung cancer patients and 611 healthy individuals followed by cfDNA extraction. Low-pass whole genome sequencing and targeted methylation sequencing were conducted and various features of cfDNA were evaluated. With our customized algorithm using the most optimal features, the ensemble stacked model was constructed, called ESim-seq (Early Screening tech with Integrated Model). In the independent validation cohort, the ESim-seq model achieved an area under the curve (AUC) of 0.948 (95 % CI: 0.915-0.981), with a sensitivity of 79.3 % (95 % CI: 71.5-87.0 %) across all stages at a specificity of 96.0 % (95 % CI: 90.6-100.0 %). Specifically, the sensitivity of the ESim-seq model was 76.5 % (95 % CI: 67.3-85.8 %) in stage I patients, 100 % (95 % CI: 100.0-100.0 %) in stage II patients, 100 % (95 % CI: 100.0-100.0 %) in stage III patients and 87.5 % (95 % CI: 64.6%-100.0 %) in stage IV patients in the independent validation cohort. Besides, we constructed LCSC model (Lung Cancer Subtype multiple Classification), which was able to accurately distinguish patients with small cell lung cancer from those with non-small cell lung cancer, achieving an AUC of 0.961 (95 % CI: 0.949-0.957). The present study has established a framework for assessing cfDNA features and demonstrated the benefits of integrating multiple features for early detection of lung cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Internet Medical and System Applications of National Engineering Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
- Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., The State Key Laboratory of Neurology and Oncology Drug Development, Nanjing, China; Cancer Center, The First Affiliated Hospi…
- Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., The State Key Laboratory of Neurology and Oncology Drug Development, Nanjing, China.
- Internet Medical and System Applications of National Engineering Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. Electronic address: zhaojie@zzu.edu.cn.
Förderung
- Key Scientific Research Project of Colleges and Universities in Henan Province
- Zhengzhou University
- Wu Jieping Medical Foundation
- National Natural Science Foundation of China
- First Affiliated Hospital of Zhengzhou University
- Key Research and Development Program of Hunan Province of China
Zitieren
APA
Xue, R., Li, X., Yang, L., Yang, M., Zhang, B., Zhang, X., Li, L., Duan, X., Yan, R., He, X., Cui, F., Wang, L., Wang, X., Wu, M., Zhang, C., & Zhao, J. (2024). Evaluation and integration of cell-free DNA signatures for detection of lung cancer. Cancer Letters, 604, 217216. https://doi.org/10.1016/j.canlet.2024.217216
Vancouver
Xue R, Li X, Yang L, Yang M, Zhang B, Zhang X, et al. Evaluation and integration of cell-free DNA signatures for detection of lung cancer. Cancer Letters. 2024;604:217216. doi:10.1016/j.canlet.2024.217216
BibTeX
@article{Xue2024,
author = {Xue, Ruyue and Li, Xiaomin and Yang, Lu and Yang, Meijia and Zhang, Bei and Zhang, Xu and Li, Lifeng and Duan, Xiaoran and Yan, Rui and He, Xianying and Cui, Fangfang and Wang, Linlin and Wang, Xiaoqiang and Wu, Mengsi and Zhang, Chao and Zhao, Jie},
title = {Evaluation and integration of cell-free DNA signatures for detection of lung cancer},
journal = {Cancer Letters},
year = {2024},
volume = {604},
pages = {217216},
doi = {10.1016/j.canlet.2024.217216}
}
EUVIMED